Literature DB >> 19238553

The multidisciplinary management of osteosarcoma.

Noah Federman1, Nicholas Bernthal, Fritz C Eilber, William D Tap.   

Abstract

OPINION STATEMENT: Patients with suspected or confirmed osteosarcoma should be evaluated and treated at a comprehensive cancer center within a multidisciplinary sarcoma program that includes pediatric, medical and radiation oncologists, orthopedic and surgical oncologists, musculoskeletal pathologists, and radiologists. Successful treatment involves proper diagnosis, neoadjuvant and adjuvant multi-agent chemotherapy, and aggressive surgery with an emphasis toward limb-preserving procedures. Treatment of osteosarcoma should be undertaken within the framework of large cooperative group clinical trials for children, adolescents, and adults. Patients treated with osteosarcoma should be followed closely both for recurrence of disease and for development of late effects of the treatment of their cancer. The treatment of metastatic, recurrent and/or refractory disease is more controversial. Despite advances in systemic treatment, surgical technique, and supportive care, the overall outcome is still poor.

Entities:  

Mesh:

Year:  2009        PMID: 19238553     DOI: 10.1007/s11864-009-0087-3

Source DB:  PubMed          Journal:  Curr Treat Options Oncol        ISSN: 1534-6277


  72 in total

1.  A systematic review of the role of pulmonary irradiation in the management of primary bone tumours.

Authors:  J S Whelan; R J Burcombe; J Janinis; A M Baldelli; A M Cassoni
Journal:  Ann Oncol       Date:  2002-01       Impact factor: 32.976

2.  Etiology and results of tumor endoprosthesis revision surgery in 64 patients.

Authors:  P Z Wirganowicz; J J Eckardt; F J Dorey; F R Eilber; J M Kabo
Journal:  Clin Orthop Relat Res       Date:  1999-01       Impact factor: 4.176

3.  Prognostic significance of alkaline phosphatase measurements in patients with osteogenic sarcoma receiving chemotherapy.

Authors:  W P Thorpe; J J Reilly; S A Rosenberg
Journal:  Cancer       Date:  1979-06       Impact factor: 6.860

4.  Neoadjuvant chemotherapy for osteosarcoma of the extremity: long-term results of the Rizzoli's 4th protocol.

Authors:  G Bacci; A Briccoli; S Ferrari; A Longhi; M Mercuri; R Capanna; D Donati; S Lari; C Forni; M DePaolis
Journal:  Eur J Cancer       Date:  2001-11       Impact factor: 9.162

5.  Treatment of osteosarcoma of the extremities with the T-10 protocol, with emphasis on the effects of preoperative chemotherapy with single-agent high-dose methotrexate: a Scandinavian Sarcoma Group study.

Authors:  G Saeter; T A Alvegård; I Elomaa; A E Stenwig; T Holmström; O P Solheim
Journal:  J Clin Oncol       Date:  1991-10       Impact factor: 44.544

6.  Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities.

Authors:  Gennady N Machak; Sergey I Tkachev; Yuriy N Solovyev; Pavel A Sinyukov; Stanislav M Ivanov; Natalya V Kochergina; Alexey D Ryjkov; Valery V Tepliakov; Benjamin Y Bokhian; Valeria V Glebovskaya
Journal:  Mayo Clin Proc       Date:  2003-02       Impact factor: 7.616

7.  High-dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases.

Authors:  Peter M Anderson; Gregory A Wiseman; Angela Dispenzieri; Carola A S Arndt; Lynn C Hartmann; William A Smithson; Brian P Mullan; Oyvind S Bruland
Journal:  J Clin Oncol       Date:  2002-01-01       Impact factor: 44.544

8.  Second solid malignancies among children, adolescents, and young adults diagnosed with malignant bone tumors after 1976: follow-up of a Children's Oncology Group cohort.

Authors:  Robert Goldsby; Cynthia Burke; Rajaram Nagarajan; Tianni Zhou; Zhengjia Chen; Neyssa Marina; Debra Friedman; Joseph Neglia; Paul Chuba; Smita Bhatia
Journal:  Cancer       Date:  2008-11-01       Impact factor: 6.860

9.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group.

Authors:  Paul A Meyers; Cindy L Schwartz; Mark D Krailo; John H Healey; Mark L Bernstein; Donna Betcher; William S Ferguson; Mark C Gebhardt; Allen M Goorin; Michael Harris; Eugenie Kleinerman; Michael P Link; Helen Nadel; Michael Nieder; Gene P Siegal; Michael A Weiner; Robert J Wells; Richard B Womer; Holcombe E Grier
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

10.  Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651.

Authors:  Allen M Goorin; Douglas J Schwartzentruber; Meenakshi Devidas; Mark C Gebhardt; Alberto G Ayala; Michael B Harris; Lee J Helman; Holcombe E Grier; Michael P Link
Journal:  J Clin Oncol       Date:  2003-04-15       Impact factor: 44.544

View more
  51 in total

1.  Inhibition of NADPH oxidase 2 induces apoptosis in osteosarcoma: The role of reactive oxygen species in cell proliferation.

Authors:  Kazumasa Kitamoto; Yuji Miura; Sivasundaram Karnan; Akinobu Ota; Hiroyuki Konishi; Yoshitaka Hosokawa; Keiji Sato
Journal:  Oncol Lett       Date:  2018-03-19       Impact factor: 2.967

Review 2.  Imaging pediatric bone sarcomas.

Authors:  Sue C Kaste
Journal:  Radiol Clin North Am       Date:  2011-06-16       Impact factor: 2.303

3.  Canine tumor cross-species genomics uncovers targets linked to osteosarcoma progression.

Authors:  Melissa Paoloni; Sean Davis; Susan Lana; Stephen Withrow; Luca Sangiorgi; Piero Picci; Stephen Hewitt; Timothy Triche; Paul Meltzer; Chand Khanna
Journal:  BMC Genomics       Date:  2009-12-23       Impact factor: 3.969

4.  Diagnostic value of circulating microRNAs for osteosarcoma in Asian populations: a meta-analysis.

Authors:  Xi Wang; Yujie Ning; Lei Yang; Huan Liu; Cuiyan Wu; Sen Wang; Xiong Guo
Journal:  Clin Exp Med       Date:  2016-04-22       Impact factor: 3.984

5.  Corosolic acid inhibits the proliferation of osteosarcoma cells by inducing apoptosis.

Authors:  Yong Jia; Hua Yuan; Shouqin Shan; Gang Xu; Jie Yu; Chenguang Zhao; Xiang Mou
Journal:  Oncol Lett       Date:  2016-09-26       Impact factor: 2.967

6.  Synergistic effect of low-dose cucurbitacin B and low-dose methotrexate for treatment of human osteosarcoma.

Authors:  Dhong Hyun Lee; Nils H Thoennissen; Catherine Goff; Gabriela B Iwanski; Charles Forscher; Ngan B Doan; Jonathan W Said; H Phillip Koeffler
Journal:  Cancer Lett       Date:  2011-03-26       Impact factor: 8.679

7.  Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy.

Authors:  Yimin Ma; Yongxin Ren; Ethan Q Han; Huiwu Li; Di Chen; Joshua J Jacobs; Steven Gitelis; Regis J O'Keefe; Yrjö T Konttinen; Guoyong Yin; Tian-Fang Li
Journal:  Biochem Biophys Res Commun       Date:  2013-01-03       Impact factor: 3.575

8.  Analysis of long-term outcome of image-guided volumetric modulated arc therapy (VMAT) for primary malignant tumor of the cervical spine.

Authors:  Ping Jiang; Xile Zhang; Weijuan Jiang; Na Meng; Abudureyimujiang Aili; Junjie Wang
Journal:  Cancer Biol Ther       Date:  2020-04-16       Impact factor: 4.742

9.  Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.

Authors:  Qiang Lu; Gang Lv; Andre Kim; Jong-Myung Ha; Suhkman Kim
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

10.  Palliative embolization for osteosarcoma.

Authors:  Andreas F Mavrogenis; Giuseppe Rossi; Eugenio Rimondi; Teresa Calabrò; Panayiotis J Papagelopoulos; Pietro Ruggieri
Journal:  Eur J Orthop Surg Traumatol       Date:  2013-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.